Currently, CB-011, which is an anti-BCMA allo-CAR-Ts engineered with CRISPR/CAS12a to knock out both TRAC and β2M while co-expressing a β2M-HLA-E fusion peptide, is under evaluation in the CaMMouflage Phase 1 trial and has presented encouraging preclinical data, resulting in noticeably enhanced durability of anti-tumor activity (87). Here, B2M is linked to neoplasm.